Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: conteltinib, defactinib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 238 | 0.73 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 4511
Sealed predictions
- PTK2B in dopamine neurons, braak-0.58 (p 0.104) → -0.23 (p 0.549)receipt 4518
Swarm cases
receipt 4518: PTK2B in dopamine neurons, braak
- power
- full sample -0.44 (p 0.070, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.42 (p 0.082, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range -0.55 to -0.36, sign flips 0; without severely affected donors -0.44 (p 0.070, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PTK2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts